Healthy Subjects
Conditions
Brief summary
The main objectives of this first-into-man study were to investigate the safety, tolerability and the pharmacokinetic profile of single oral doses of ACT-541468 in healthy male adults. Pharmacodynamic effects (through a battery of Central Nervous System tests) were also assessed.
Detailed description
The study consisted of ascending dose groups; each dose group was investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo). In addition, the study included a biocomparison part (dose group 2), an absolute bioavailability part (dose group 4), and a mass balance / metabolism part (dose group 3).
Interventions
DRUGACT-541468 (Formulation A)
Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
DRUGACT-541468 (Formulation B)
Soft gelatin capsules for oral administration formulated at the strength of 25 mg
DRUGPlacebo (Formulation A)
Hard capsules matching ACT-541468 Formulation A
DRUGPlacebo (Formulation B)
Soft capsules matching ACT-541468 Formulation B
DRUG14C-labeled ACT-541468
Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
DRUGPlacebo tracer
Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
Sponsors
Idorsia Pharmaceuticals Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Key inclusion Criteria: * Signed informed consent prior to any study-mandated procedure. * Males aged from 18 to 45 years (inclusive) at screening. * Body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening. * Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) between 100-145 mmHg, 50-90 mmHg and 45-90 bpm (all inclusive) at screening, respectively. * Healthy on the basis of physical examination,electrocardiogram and laboratory tests. Key
Exclusion criteria
* Known hypersensitivity to any excipients of the drug formulations. * History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs. * History of narcolepsy or cataplexy or modified Swiss narcolepsy scale total score \< 0 at screening. * Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with treatment-emergent adverse events and serious adverse events | Day 8 | Collection of any adverse event at each dose level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to reach Cmax (tmax) of ACT-541468 | From pre-dose up to 168 hours post-dose | tmax was directly derived from the observed plasma concentrations of ACT-541468 for each dose level |
| Terminal half-life (t1/2) of ACT-541468 | From pre-dose up to 168 hours post-dose | t1/2 was calculated from the terminal rate constant obtained from the plasma concentrations-time curves of ACT-541468, at each dose level |
| Area under the plasma concentration-time curves [AUC(0-inf)] of ACT-541468 | From pre-dose up to 168 hours post-dose | AUC(0-inf) is the area under the plasma concentration-time curves of ACT-541468, calculated from time 0 (pre-dose) to extrapolated infinite time, at each dose level |
| Percentage of dose excreted in feces and urine | From pre-dose up to 168 hours post-dose | Percentage of oral dose of 14C-labeled ACT-541468 excreted in feces (FPE), urine (UPE) and both, as determined in the dose group 3 |
| Absolute bioavailability (F) of ACT-541468 | Up to 96 hours post-dose | Absolute bioavailability was determined for dose group 4 and defined as the ratio of AUC(0-inf) after oral administration of ACT-541468 and after intravenous infusion of 14C-labeled ACT-541468 (tracer) |
| Maximum plasma concentration (Cmax) of ACT-541468 | From pre-dose up to 168 hours post-dose | Cmax was directly derived from the observed plasma concentrations of ACT-541468 for each dose level |
Other
| Measure | Time frame |
|---|---|
| Change from baseline in adaptive tracking | At baseline till 10 hours after study drug administration |
| Chnage from baseline in Bond and Lader visual analog scale (B&L VAS)l | At baseline till 10 hours after study drug administration |
| Change from baseline in body sway | At baseline till 10 hours after study drug administration |
| Change from baseline in saccadic peak velocity (SPV) | At baseline till 10 hours after study drug administration |
Countries
Netherlands
Outcome results
None listed